Explore › Outcome › Acute myeloid leukemia in complete remission
Outcome

Acute myeloid leukemia in complete remission

Also known as: Acute myeloid leukaemia in complete remission Acute myeloid leukaemia in full remission Acute myeloid leukemia in complete remission Acute myeloid leukemia in complete remission (disorder) Acute myeloid leukemia in full remission Complete remission (CR) rate after first induction course CR AML
3 findings 1 paper 4 related entities View in graph →

Related entities

interventions
FLT3 mutation testing1
conditions
Pediatric acute epiglottitis and supraglottitis1
populations
Children1
studys
PMC33689971

Findings (27)

None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →
None
decline

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Size: 60% vs 93%
PMC3368997
Finding details → · Paper → · Graph →

Papers (1)